Enzalutamide is a prescription medicine used in specific prostate cancer treatment settings. It belongs to a class of medicines that target androgen receptor signaling, an important pathway in prostate cancer biology.
The appropriate use of enzalutamide depends on the patient’s cancer stage, hormone sensitivity, metastatic status, previous treatment, symptoms, overall health, and applicable regulatory approval.
Prostate Cancer and Androgen Signaling
Many prostate cancer cells depend on androgen receptor signaling.
Androgens such as testosterone can activate androgen receptors inside prostate cancer cells. Activation of these receptors can stimulate signaling pathways that support cancer-cell growth.
Enzalutamide interferes with this process.
By inhibiting androgen receptor signaling, it reduces the ability of prostate cancer cells to respond to androgen stimulation.
Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide can be used in certain men with metastatic hormone-sensitive prostate cancer (mHSPC).
In this setting, the prostate cancer has spread beyond the prostate, but it remains responsive to androgen deprivation.
Treatment commonly involves androgen deprivation therapy, and enzalutamide may form part of a systemic treatment strategy in appropriate patients.
The precise approved regimen and combination depend on the applicable regulatory authority. The EMA lists enzalutamide with hormone therapy as an approved treatment option for specified men with metastatic hormone-sensitive prostate cancer.
Metastatic Castration-Resistant Prostate Cancer
Another major treatment setting is metastatic castration-resistant prostate cancer (mCRPC).
Castration-resistant prostate cancer means that the disease continues to progress despite testosterone suppression to castrate levels.
Enzalutamide can inhibit androgen receptor signaling even when conventional androgen deprivation has already reduced circulating testosterone.
Depending on regulatory approval and clinical circumstances, enzalutamide may be used after docetaxel or in selected patients before chemotherapy where chemotherapy is not yet clinically indicated.
Non-Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is also approved in certain settings for men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
In this situation, there is evidence of biochemical or clinical progression despite castration-level testosterone, but conventional imaging does not demonstrate distant metastatic disease.
Treatment selection depends on factors such as disease characteristics, PSA kinetics, prior treatment, risk profile, and clinical guidance.
Biochemical Recurrence
Some regulatory approvals also include a specific setting involving high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer.
The EMA describes an indication for certain men who are not suitable for salvage radiotherapy, where enzalutamide may be used as monotherapy or together with androgen deprivation therapy according to the approved indication.
Biochemical recurrence should therefore be evaluated carefully rather than being treated as a single uniform disease category.
What Does Treatment Aim to Do?
The goal of enzalutamide treatment depends on the clinical setting.
Treatment may aim to:
- Suppress androgen receptor signaling
- Delay disease progression
- Control prostate cancer
- Reduce the likelihood of cancer progression in selected settings
- Maintain disease control
- Address metastatic disease as part of systemic therapy
The specific goal should be explained by the treating oncologist.
Enzalutamide should not be described as a guaranteed cure.
Enzalutamide With Androgen Deprivation Therapy
Enzalutamide may be prescribed alongside androgen deprivation therapy in appropriate treatment settings.
For men with mHSPC or CRPC who have not undergone surgical castration, current European product information specifies continuation of medical castration with an LHRH analogue.
This illustrates why prostate cancer treatment should be managed as a complete therapeutic strategy rather than as an isolated tablet.
Treatment After Previous Therapy
The appropriate place of enzalutamide in treatment depends on the patient’s previous therapies.
Relevant factors may include:
- Previous androgen deprivation therapy
- Previous chemotherapy
- Disease progression
- Metastatic status
- Symptoms
- Previous response to treatment
- Other available therapies
- Patient preference and overall health
An oncologist evaluates these factors before selecting treatment.
How Treatment Response Is Assessed
Treatment response may be assessed using a combination of:
PSA
PSA can provide useful information about prostate cancer activity, although PSA alone does not provide a complete picture of treatment response.
Imaging
CT, MRI, bone imaging, PET-based imaging, or other scans may be used depending on the clinical situation.
Symptoms
Pain, urinary symptoms, fatigue, appetite, weight changes, and other symptoms can provide information about disease status and treatment effects.
Clinical Assessment
The oncologist considers laboratory findings, imaging, symptoms, examination findings, treatment tolerance, and disease history together.
Duration of Treatment
Enzalutamide may be continued for as long as the treating healthcare professional considers that the treatment remains appropriate and tolerated, subject to the applicable indication and treatment goals.
Treatment may be interrupted, adjusted, or discontinued because of disease progression, adverse reactions, patient factors, or other clinical considerations.
Patients should not independently stop treatment.
Important Safety Considerations
Because enzalutamide affects androgen receptor signaling and can interact with other medicines, treatment requires appropriate medical supervision.
Important concerns include:
- Seizures
- Ischemic heart disease
- Hypertension
- Falls
- Fractures
- Hypersensitivity
- Neurological symptoms
- Drug interactions
The EMA specifically identifies seizure and ischemic heart disease as important safety concerns associated with enzalutamide.
Who Decides Whether Enzalutamide Is Appropriate?
The treating oncology team should determine whether enzalutamide is appropriate.
The decision can depend on:
- Cancer diagnosis
- Disease stage
- Metastatic status
- Hormone sensitivity
- Previous treatment
- Current laboratory results
- Other medical conditions
- Other medicines
- Regulatory indication
- Potential benefits and risks
Treatment Availability and Regulatory Differences
Enzalutamide’s approved uses can differ between countries.
The EMA’s approved indications should not automatically be interpreted as the indications approved by every national regulator.
Patients should therefore follow the label and treatment guidance applicable to their country.
Enzamide 40 mg
For this website, Enzamide 40 mg is the supplied product associated with enzalutamide and Everest.
The product-specific details should always be checked against the actual package and official documentation supplied for the relevant market.
Final Summary
Enzalutamide is an androgen receptor signaling inhibitor used in defined prostate cancer treatment settings.
Its clinical role includes selected cases of:
- Metastatic hormone-sensitive prostate cancer
- Metastatic castration-resistant prostate cancer
- High-risk non-metastatic castration-resistant prostate cancer
- Certain high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer
Its role is determined by the patient’s disease characteristics and the applicable regulatory indication.
Enzalutamide is a prescription medicine and should be initiated and monitored by an experienced healthcare professional.
Patients considering Enzamide 40 mg should discuss the medicine, expected treatment goals, risks, interactions, monitoring, and alternatives with their oncology team before treatment.